Search Results - containing

7 Results

Sort By:

Process for Practical, Scalable, Commercially-viable Method for the Synthesis of Enantio-enriched Aminoalcohols, Including the Novel Antifungal VT-1129 Used to Treat Cryptococcal Meningitis

This technology relates to the discovery and development of a practical, scalable, and commercially viable method for the synthesis of the novel antifungal VT-1129. Cryptococcal meningitis (CM) is a fungal infection that is particularly prevalent in immune-compromised patients and can be treated by VT-1129. CM has a current estimated patient population...

Published: 7/25/2024 | Inventor(s): Mark Behnke, Scott David, Douglas Fry, William Hoekstra, Christopher Yates, Asaf Alimardanov

Keywords(s): Acid, Alcohol, Aminoalcohols, Benzenesulfonic, BSA., Co-crystal, Containing, Derivatives, Enantioenriched, Fragment, Including, Listed LPM Nguyen-Antczak as of 4/15/2015, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, PROCESS, Synthesis, Tertiary, THOSE, VEXXXX, VT-1129, WMXXXX

Category(s): Application > Consumer Products, TherapeuticArea > Neurology

Improved simian HIV (SHIV) prevention in non-human primate models with chemoprophylaxis combination that can be taken in one or two oral doses before or after exposure

HIV and AIDS remain persistent problems for the United States and countries around the world. In 2015, nearly 40,000 people were diagnosed with HIV in the US alone. Pre-exposure prophylaxis (PrEP) can help prevent HIV infections in people who are not infected with HIV but are at high risk of becoming infected with HIV. PrEP involves taking daily medications...

Published: 7/25/2024 | Inventor(s): Ivana Massud, Walid Heneine, Jose Garcia Lerma

Keywords(s): Chemoprophylaxis, Combinations, Containing, HIV, Improved, Inhibitors, Integrase, NCHHSTP, NCHHSTP-DHAP, Reverse, TRANSCRIPTASE

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing

Dengue Vaccines: Tools for Redirecting the Immune Response for Safe, Efficacious Dengue Vaccination

This CDC-developed invention relates to dengue vaccines that have been specifically developed for improved efficacy and directed immune response to avoid antibody-dependent enhancement (ADE) safety issues that, theoretically, may be associated with dengue vaccines and vaccinations. Dengue viral infection typically causes a debilitating but non-lethal...

Published: 7/25/2024 | Inventor(s): Wayne Crill, Holly Hughes, Brent Davis, Gwong-Jen Chang

Keywords(s): CDC Docket Import, CDC Docket Import CDC Prosecuting, Containing, Cross-Reactive, DB4BXX, DB4XXX, DC5BXX, DC5XXX, DCXXXX, DDXXXX, DENGUE, DNA vaccine, DXXXXX, E-GLYCOPROTEIN, Eliminate, Epitopes, Immunodominant, insect, Insects, Mosquito, Mosquitoes, MULTIVALENT, Mutations, OID-NCEZID-DVBD, POLYPEPTIDES, Serotype, Serotypes, That, Vacccination, Vaccine, Vector-borne, Vector-borne diseases, virus, VLXXXX, WJXXXX, WMXXXX, XCXXXX, XEXXXX, YBXXXX, YCXXXX

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Infectious Disease, Application > Vaccines, Application > Consumer Products, Application > Research Materials, Application > Diagnostics

Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology

Due to the disorganized nature of blood vessels that run through tumors, chemotherapeutic agents often fail to penetrate tumors and kill cancer cells at the tumor’s center. This can lead to ineffective chemotherapeutic treatments, because tumors can quickly grow back if the entire tumor is not destroyed. NIH researchers have developed a therapeutic...

Published: 7/25/2024 | Inventor(s): Stephen Leppla, Shihui Liu, Thomas Bugge, Diane Peters, Jie Liu, Alexander Wein, Kuang-Hua Chen, Christopher Bachran, Damilola Phillips, Henning Hansen, Sarah Arnett, Clinton Leysath

Keywords(s): Against, AMOUNTS, Anthrax, AnthraxToxins, ANTIGEN, B, CA1BXX, CB1AXX, CB1BXX, CB1XXX, CB3CXX, CBXXXX, Cells, Cell-Surface, CMG2, COMPLEMENTARY, CONTAIN, Containing, CXXXXX, Cytolethal, Distending, EFFICACY, Efficient, ENGINEERED, exclusively, Exploiting, FELINE, FELINE Leukemia, FORM, Fusion, fusion proteins, Having, High, IC2-PA, Identifying, Improved, Leppla, Listed LPM McCue as of 4/15/2015, MARKER, Metallo..., MULTIMERIC, Mutated, Nature, Octamers, Patent Category - Biotechnology, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Protective, Protein, proteins, SOLID, SPECIFICALLY, Specificity, Strong, TARGET, Targeting, That, THERAPY, toxin, TOXINS, tumor, Types, UAXXXX, VARIANTS, VASCULATURE, VETERINARY

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Diagnostics, TherapeuticArea > Rare / Neglected Diseases

Capsid-Free AAV Vectors for Gene Delivery and Their Use for Gene Therapy

The invention concerns novel capsid-free AAV vectors that can be used for gene delivery and gene therapy applications. The invention provides for a linear nucleic acid molecule comprising in this order: a first adeno-associated virus (AAV) inverted terminal repeat (ITR), a nucleotide sequence of interest, and a second AAV ITR, wherein said nucleic acid...

Published: 7/25/2024 | Inventor(s): Lina Li, Luis Garcia, Cyriaque Beley, Thomas Voit, Robert Kotin

Keywords(s): AAV, Cell, Clonal, Containing, DNA, GB2AXX, Lines, Listed LPM Reichman as of 4/15/2015, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Rescueable, Sf9, STABLE, Vector, VPXXXX, WJXXXX, XEXXXX, YAXXXX, YBXXXX

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Dental, TherapeuticArea > Endocrinology, Application > Therapeutics, TherapeuticArea > Ophthalmology, TherapeuticArea > Oncology, TherapeuticArea > Cardiology, TherapeuticArea > Infectious Disease

Recombinant Baculoviruses Containing Inserts of the Major Structural Genes (vp1) of the Human Polyomaviruses JCV and BKV

The development of sensitive and specific tests for JC virus and BK virus activity may provide tools essential in the steps required to find a treatment for these fatal infections. This invention describes a Recombinant Vpl protein (rVp1) that can be used 1) as an antigen source for ELISA assays 2) for studies of viral proteins in cells and 3) for...

Published: 7/25/2024 | Inventor(s): Peter Jensen, Eugene Major

Keywords(s): Baculovirus, BKV, Containing, DA4BXX, DA4XXX, DAXXXX, DDXXXX, DXXXXX, GENES, Human, Inserts, JCV, MAJOR, Polyomavirus Infections, Polyomaviruses, recombinant, STRUCTURAL, VP1

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Diagnostics, Application > Research Materials

Development of Dengue Virus Type 3 Vaccine Candidates

The disease burden associated with dengue virus infection has increased over the past several decades in the tropical and semi-tropical regions of the world, where over 2 billion people live at risk of dengue infection. Annually, there are an estimated fifty (50) to one hundred (100) million cases of dengue fever, making development of an effective...

Published: 7/25/2024 | Inventor(s): Joseph Blaney, Brian Murphy, Stephen Whitehead

Keywords(s): 1, 2, 3, 30, 3'-UTR, CANDIDATES, CONSISTING, Containing, Contiguous, DA4BXX, DA4XXX, DAXXXX, DC5BXX, DC5XXX, DCXXXX, DDXXXX, Deletion, DELETIONS, Delta30, DEN4, DENGUE, Dengue (Flaviviridae), DENGUE FEVER, Dervived, Development, DXXXXX, Either, Genome, Hepatitis A, Hepatitis D, Hepatitis E, Iin, MULTIPLE, Nucleotdies, Nucleotide, ONE, Q fever, Regions, THAN, TYPE, UAXXXX, UBXXXX, Vaccine, virus

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Rare / Neglected Diseases, Application > Research Materials, Application > Diagnostics, Application > Vaccines, TherapeuticArea > Infectious Disease